Cargando…

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala

INTRODUCTION: In 2011 Uganda recommended boosted atazanavir (ATV/r) as the preferred PI for second line due to once daily dosing, replacing aluvia (LPV/r) [1, 2]. The evidence was based on the BMS O45 trial, of LPV/r vs ATV/r was performed in a high-income setting, on patients with prior PI use and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laker, Eva, Mambule, Ivan, Nalwanga, Damalie, Musaazi, Joseph, Kiragga, Agnes, Parkes-Ratanshi, Rosalind
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P260
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225351/ https://www.ncbi.nlm.nih.gov/pubmed/25397536 http://dx.doi.org/10.7448/IAS.17.4.19792

Ejemplares similares

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Six-Month Outcomes of Heart Transplant Recipients Infected by COVID-19
por: Diakos, N., et al.
Publicado: (2021)

Diagnostic et prise en charge de la fibrose post-COVID
por: Gader, N., et al.
Publicado: (2022)

Cardiovascular Comorbidities and Covid-19 in Women
por: Weizman, O., et al.
Publicado: (2021)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Quantifying retention during pre-antiretroviral treatment in a large urban clinic in Uganda
por: Castelnuovo, Barbara, et al.
Publicado: (2015)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Longitudinal patients' cohorts for impactful research and HIV care at the Infectious Diseases Institute
por: Castelnuovo, Barbara, et al.
Publicado: (2022)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

Possible misdiagnosis of HIV associated lymphoma as tuberculosis among patients attending Uganda Cancer Institute
por: Buyego, Paul, et al.
Publicado: (2017)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years
por: Lima, Viviane D, et al.
Publicado: (2014)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study
por: Hocqueloux, Laurent, et al.
Publicado: (2012)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

High burden of untreated syphilis, drug resistant Neisseria gonorrhoeae, and other sexually transmitted infections in men with urethral discharge syndrome in Kampala, Uganda
por: Hamill, Matthew M., et al.
Publicado: (2022)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
por: Smith, Christiana, et al.
Publicado: (2016)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
por: Khan, Saif Ahmad, et al.
Publicado: (2020)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Adherence monitoring methods to measure virological failure in people living with HIV on long-term antiretroviral therapy in Uganda
por: Okoboi, Stephen, et al.
Publicado: (2022)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

Exploring attitudes and perceptions of patients and staff towards an after-hours co-pay clinic supplementing free HIV services in Kampala, Uganda
por: Twimukye, Adelline, et al.
Publicado: (2017)

Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda
por: Seden, K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7nrdo7om5kcfosgm4vhlah4jkh